Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead The Charge In Pioneering New Treatments Delveinsight

A snapshot of the Pipeline Sickle Cell Disease Drugs mentioned in the report:

Learn more about the sickle cell disease research companies @ Sickle Cell Disease Clinical Trials

Stuti Mahajan, Functional Head of Consulting at DelveInsight, said that the sickle cell disease market is expected to shift toward more targeted and disease-modifying therapies, supported by the advancement of oral metabolic therapies, gene therapies, and fetal hemoglobin–inducing approaches. Positive Phase III data for etavopivat and the regulatory progress of mitapivat could expand pharmacological treatment options, while programs such as BEAM-101 and CS-206 may drive longer-term disease modification. Growing investment in novel mechanisms, including G9a inhibition, TMPRSS6 inhibition, hemopexin replacement, and anti-inflammatory approaches, is expected to further diversify the pipeline. Overall, the market outlook remains innovation-driven, with increasing emphasis on reducing VOCs, improving hemoglobin levels, and achieving durable treatment responses.

Recent Developments in Sickle Cell Disease Treatment Space

• In July 2026, Agios Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for this sNDA, submitted under the FDA's accelerated approval pathway, is November 1, 2026.
• In June 2026, CorrectSequence Therapeutics Co., Ltd. announced that the first sickle cell disease (SCD) patient being treated in China with its high-precision base-editing therapy CS-206 has remained free of vaso-occlusive crises (VOCs) for more than 15 months following engraftment. Starting from 60 Days after the last red-cell transfusion, the patient has remained free from VOCs and anemia for 13 consecutive months, achieving the primary efficacy endpoint. The follow-up data demonstrated favorable safety and efficacy of CS-206.
• In April 2026, Novo Nordisk announced the topline results from HIBISCUS, a pivotal phase III trial of once-daily oral etavopivat in adults and adolescents with sickle cell disease (SCD). The results showed that etavopivat successfully met both co-primary endpoints, demonstrating superior reduction in vaso-occlusive crises (VOCs) and superior improvement in haemoglobin (Hb) response compared to placebo.
• In March 2026, EpiFrontier Therapeutics, Inc., a biotechnology company developing transformative therapies for beta globin disorders, announced its award of up to USD 32 million in non-dilutive funding from the Japan Agency for Medical Research and Development (AMED). The grant will advance the clinical development of EPF-001, a novel small molecule G9a inhibitor designed to increase fetal hemoglobin expression in patients with sickle cell disease and beta thalassemia.
• In September 2025, Enlaza Therapeutics, the first covalent biologics platform company, announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals to utilize Enlaza's proprietary War-LockTM technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.
• In August 2025, Beam Therapeutics Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD)
• In June 2025, the US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that works via multi-immune modulation, to target a reduction in vaso-occlusive crises, which may occur via inflammation, in sickle cell disease.
• In June 2025, Beam Therapeutics Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).

Scope of the Sickle Cell Disease Pipeline Report

• Coverage: Global
• Sickle Cell Disease Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Sickle Cell Disease Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Sickle Cell Disease Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Sickle Cell Disease Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Sickle Cell Disease Therapeutics Assessment By Mechanism of Action: PK Activator, Gardos channel (KCNN4) inhibitor, cell replacement, Fetal haemoglobin expression stimulants, Gene transference, TMPRSS6 protein inhibitors, EED protein inhibitors, Increases fetal hemoglobin (HbF), and others
• Key Sickle Cell Disease Companies: Novo Nordisk, Biossil Inc., Kamau Therapeutics, Novartis, CorrectSequence Therapeutics, Disc Medicine, Inc., CSL Behring, Sanofi, Bristol-Myers Squibb, Beam Therapeutics Inc., MiNA Therapeutics, Ensoma, Inc., Reforgene Medicine, YolTech, Incisive Genetics, GluBio Therapeutics, Enlaza Therapeutics, Vertex Pharmaceuticals, and others.
• Key Sickle Cell Disease Pipeline Therapies: Etavopivat, SIL-8301, Nulabeglogene autogedtemcel, ITU512, CS-206, DISC-3405, CSL324, Rilzabrutinib, BMS-986470, BEAM-101, MTL-HBG, Research Program, RM001, YOLT-204, IG-SCD 1, GLB-005, Research Program: Drug Conjugates, and others.

Sickle Cell Disease News

Table of Contents

1.	Sickle Cell Disease Pipeline Report Introduction
2.	Sickle Cell Disease Pipeline Report Executive Summary
3.	Sickle Cell Disease Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Sickle Cell Disease Clinical Trial Therapeutics
6.	Sickle Cell Disease Pipeline: Late-Stage Products (Pre-registration)
7.	Sickle Cell Disease Pipeline: Late-Stage Products (Phase III)
8.	Sickle Cell Disease Pipeline: Mid-Stage Products (Phase II)
9.	Sickle Cell Disease Pipeline: Early-Stage Products (Phase I)
10.	Sickle Cell Disease Pipeline Therapeutics Assessment
11.	Inactive Products in the Sickle Cell Disease Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Sickle Cell Disease Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the sickle cell disease clinical trials, reach out @ Sickle Cell Disease Medication

Related Reports

Sickle Cell Disease Market

Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SCD companies, including Pfizer, Agios Pharmaceuticals, Fulcrum Therapeutics, Novo Nordisk, Scribe Therapeutics, Sanofi, and others.

Hemophilia Market

Hemophilia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia companies, including Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk, and others.

Hemophilia A Market

Hemophilia A Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia A companies, including Novo Nordisk, Ultragenyx Pharmaceutical, Sangamo Therapeutics, ASC Therapeutics, Roche, Chugai, Sanofi, Alnylam Pharmaceuticals, Pfizer, Genentech, BioMarin Pharmaceutical, HEMA Biologics, LFB Pharmaceuticals, Octapharma, CSL Behring, Octapharma, Bayer, Takeda, and others.

Hemophilia B Market

Hemophilia B Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia B companies, including UniQure Biopharma B.V., CSL Behring, Pfizer, Spark Therapeutics, Genzyme, a Sanofi Company, Alnylam Pharmaceuticals, Novo Nordisk, UniQure Biopharma B.V., ApcinteX Ltd, Freeline Therapeutics, Sangamo Therapeutics, and others.

Thalassemia Market

Thalassemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key thalassemia companies, including Novo Nordisk A/S, CorrectSequence Therapeutics Co., Ltd, Shanghai BDgene Co., Ltd., Bioray Laboratories, Mabwell (Shanghai) Bioscience Co., Ltd., Lantu Biopharma, Kind Pharmaceuticals LLC, Kanglin Biotechnology (Hangzhou) Co., Ltd., Pharmacosmos A/S, Regeneron Pharmaceuticals, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve .

CONTACT: Contact Us Shruti Thakur... +14699457679